Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug:82:102121.
doi: 10.1016/j.smrv.2025.102121. Epub 2025 Jun 25.

Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis

Affiliations
Review

Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis

Adam V Benjafield et al. Sleep Med Rev. 2025 Aug.

Abstract

Insomnia is common, is associated with major adverse medical and mental health outcomes, has a negative impact on quality of life, and has significant economic consequences. However, little is known about the global insomnia burden. This systematic review estimated the global prevalence of insomnia in adults. PubMed and Embase were searched (terms "insomnia," "prevalence," and "general population") to identify relevant peer-reviewed studies (final search 2-3 Sep 2024). Included studies had the highest data quality and lowest risk of bias, and reported clinically relevant insomnia prevalence in the general population. Insomnia prevalence estimates were applied to United Nations (UN) population data using a country-specific study (if available) or the highest-quality study (if no country-specific study). Of 1651 potential records, 18 studies (262,582 participants) were included. Thirty-one of 237 UN/World Bank-recognized countries/territories had a suitable nation-specific adult insomnia prevalence estimate. 852,325,091 adults (95 % confidence interval 830,354,161-874,309,252) were estimated to have insomnia (global prevalence: 16.2 %) and 414,967,941 were estimated to have severe insomnia (7.9 %). Insomnia and severe insomnia were more prevalent in females versus males across all age groups. The high global prevalence of insomnia disorder reinforces the need for comprehensive public health and clinical sleep health initiatives worldwide. REGISTRATION: PROSPERO: CRD42024581410.

Keywords: Global; Insomnia; Prevalence; Sleep.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest AVB, FHSK and LFM are employees of ResMed. AM is funded by the National Institutes of Health (NIH) (United States). AM also reports income related to medical education from Livanova, Powell Mansfield, Sunrise, Zoll and Eli Lilly. ResMed provided a philanthropic donation to UC San Diego, but AM has not received personal income from ResMed or medXcloud. JLM is supported by a Veterans Affairs Health Services Research & Development Research Career Scientist Award RCS 20-191 (United States). CMM reports receiving grants and personal fees from Eisai (Japan) and Idorsia (Switzerland), grants from Lallemand Health (Canada), and royalties from Mapi Research Trust, all outside the submitted work. PAC reports having an appointment to an endowed academic Chair at the University of Sydney that was established from ResMed funding, has received research support from ResMed (United States) and SomnoMed (Australia), and is a consultant to ResMed, SomnoMed, Sunrise Medical, and Eli Lilly. JLP is supported by the French National Research Agency in the framework of the Investissements d'Avenir program [Grant ANR-15-IDEX-02] and the e-Health and Integrated Care and Trajectories Medicine and MIAI Artificial Intelligence chairs of excellence from the Grenoble Alpes University Foundation (France). JLP also reports lecture fees or conference traveling grants from ResMed, Philips, Jazz Pharmaceuticals, Agiradom, and Bioprojet. EMW’s institution has received research support from the AASM Foundation (United States), Department of Defense (United States), Merck ((United States), NIH/NIA (United States), ResMed (United States), ResMed Foundation (United States), and SRS Foundation (United States). EMW has served as a scientific consultant to Axsome Therapeutics, DayZz, Eisai, EnsoData, Idorsia, Merck, Nox Health, Purdue, ResMed and Primasun, and is an equity shareholder in WellTap.

LinkOut - more resources